Treasa Carroll
Limerick
Summary
Passionate and transformational business leader with a proven track record of creating value and driving strategic growth. A highly skilled Chartered Accountant with Big 4 experience and 15 years in industry, including over 10 years in international roles. Demonstrated expertise in strategy development & execution, financial management, compliance, and operational efficiency, with a strong commitment to excellence and innovation. Now actively seeking a new opportunity to leverage global expertise and leadership skills in Ireland.
Overview
19
19
years of professional experience
Work history
CFO & Chapter Leader Finance & Commercial Operations
Roche
05.2010 - 10.2025
- Acted as strategic and financial business partner to the EMEA LATAM Pathology Regional Commercial Team (Revenue Value of ~450 million Swiss Francs) and the General Manager of the Greek Commercial Affiliate (Revenue Value of ~50 million Euros & 130 employees in 2024).
- Acted as member of the Sub Region Southeast (SRSE) Financial Managers team and Greek Commercial Diagnostic Enabling Leadership team.
- Recruitment, coaching and development of over 25 Commercial, Financial & Supply Chain experts.
- Accountable for the Greek Commercial financial results & co-ownership for the SRSE financial results encompassing short to long term business and financial ambitions.
- Ensured financial compliance to safeguard affiliate license to operate.
- Optimized local commercial, financial and supply chain processes; ranging from consolidation, standardization and digitalization of processes.
- Participated and co-lead EMEA-LATAM/SRSE financial and business initiatives.
- Roche was founded over 125 years ago and is one of the world's largest biotech companies, a leading provider of in-vitro diagnostics and a global supplier of transformative innovation solutions across major disease areas. Roche employs over 100,000 people globally with an annual turnover of over 60 billion Swiss Francs.
- Sponsor for the New Greek Strategy Development & Operating Model with Go-Live September 2024 (FTE rationalization of 10%) directing clear priorities areas & customer focuses together with embedding decision-making authorities at the right level to enhance response times to customers.
- EMEA LATAM Future of Finance Core Team member supporting the creation of the vision and driving the regional implementation; new finance personas, consolidation & standardization of business insight creation and enhanced commercial business partnering.
- Creation and roll-out of the EMEA LATAM Customer Profitability Management (Tool & Training) over 2024 and 2025 which will enable a standardized toolset and processes driving optimized top and bottom-line performance and advanced financial acumen across the region.
- Go-live of next phase of Shared Service Center Evolution 'Greece RAMP Project 2023' enabling further standardization and headcount efficiencies.
- Creation & execution of a new facility strategy for the Greek Diagnostic affiliate enabling the consolidation of Dia/Pharma country headquarters into a company owned underutilized building, elimination of a third-party leased facility & reducing capital investment requirements.
- Consolidation of the Greek Accounting, Tax, Procurement & Facility Management teams for the Diagnostic & Pharma divisions driving synergies & cost savings.
- Introduction of a New Third-Party Logistic Provider delivering on expanded services such as transit time to customer reduced by 50%, reduced environmental impact by the reduction of packaging and utilization of temperature-controlled transportation vehicles, advancement in automated processes such as the utilization of barcoding scanning for pick & pack activities whilst enabling logistic operating expense savings of over 30%.
Director of Finance
Roche Molecular Systems
02.2016 - 08.2021
- Acted as strategic and financial business partner to the VP of Molecular Reagent Operations and VP of Quality & Regulatory.
- Served as CFO for the New Jersey Molecular Operations site (Manufacturing Value of ~400 million dollars & 1,000 employees in 2020) with direct responsibility for all financial activities including operating results, budgets, annual production plan, forecasts, standard manufacturing costs, period costs, net working capital, impairment review, general accounting, cost accounting, and financial analysis.
- Acted as the Operations Finance liaison for the Molecular Reagent Lifecycle Management Leadership teams supporting strategic evaluations through the Product lifecycle ~ development through to decline.
- Supported multiple post-acquisition entities transitions & optimization within the global operations network.
- Led all financial aspects related to the manufacturing activities of the Molecular Reagent network site/s encompassing approximately 400 different diagnostics reagents for oncology, blood screening, virology, microbiology and genomics.
- Recruited, coached and developed a team of 5 Senior Financial Analysts.
- Provided concise and action oriented financial information in the Molecular Reagent Operations leadership and Global Operations Finance & Strategy leadership team meetings.
- Established and implemented internal procedures for control, protection of assets and for certification of financial statements and assurance reporting in accordance with international accounting standards and guidelines.
- 10X increase in COVID Reagent production capacity to support the pandemic through headcount, workforce shift enlargements (move to 24hrs shifts / 7 days) & equipment expansion supported by business case modelling to enable headcount (over 500 people) and CAPEX investment approvals (over 100 million dollars investment).
- Integration & expansion of Novel Molecular Point of Care technologies supported by business case modelling to enable headcount & CAPEX approvals (over 30 million dollars investment) and the introduction of SAP ERP to ensure financial transparency and governance.
- Centralization of Molecular Reagent Manufacturing driving economies of scale, strengthening quality management and elimination of 3 sites and their associated fixed costs.
- Creation and endorsement for the facility upgrade & expansion of the New Jersey Molecular Manufacturing site (over 200 million dollars investment).
Auditing Department
PricewaterhouseCoopers
Limerick, Ireland
09.2006 - 04.2010
Skills
- Financial reporting analysis
Timeline
Director of Finance
Roche Molecular Systems
02.2016 - 08.2021
CFO & Chapter Leader Finance & Commercial Operations
Roche
05.2010 - 10.2025
Auditing Department
PricewaterhouseCoopers
09.2006 - 04.2010